Key result
LMNA mutations drive cardiomyopathy via nuclear mechanical instability, gene dysregulation, prelamin A toxicity, and mTOR activation.
Understanding the underlying molecular mechanisms of LMNA cardiomyopathies highlights potential new therapeutic avenues, such as mTOR inhibition and targeting prelamin A processing.
LMNA cardiomyopathy mechanisms support hypothesis-generating trials of mTOR inhibition; does not yet inform clinical practice.
The nuclear lamina is a critical structural domain for the maintenance of genomic stability and whole-cell mechanics. Mutations in the LMNA gene, which encodes nuclear A-type lamins lead to the disruption of these key cellular functions, resulting in a number of devastating diseases known as laminopathies. Cardiomyopathy is a common laminopathy and is highly penetrant with poor prognosis. To date, cell mechanical instability and dysregulation of gene expression have been proposed as the main mechanisms driving cardiac dysfunction, and indeed discoveries in these areas have provided some promising leads in terms of therapeutics. However, important questions remain unanswered regarding the role of lamin A dysfunction in the heart, including a potential role for the toxicity of lamin A precursors in LMNA cardiomyopathy, which has yet to be rigorously investigated.
No takes yet. Share an insight, caveat, or question.
Brayson et al. (2017) conducted a review in LMNA cardiomyopathy. LMNA mutations was evaluated. LMNA mutations drive cardiomyopathy through structural mechanical instability and dysregulated gene expression, with emerging potential mechanisms including prelamin A toxicity and mTOR hyperactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: